Antibodies and methods for making and using them
The invention provides antibodies, including chimeric human antibodies, recombinant antibodies, synthetic anti-bodies, and the nucleic acids encoding them, and methods for making and using these immunoglobulins. The invention provides recombinant and synthetic polypeptide and nucleic acid embodiments of these polypeptides and/or antibodies. The invention also provides polypeptides comprising, or consisting of, consensus human framework regions, or “Independently Consensused Frameworks (ICFs)”, nucleic acids encoding them, and libraries and kits comprising these ICFs and/or antibodies of the invention, individually and in combinatorial libraries and combinations.
1. A method for treating or ameliorating a B-cell mediated disease comprising:
(a) providing a composition comprising an antibody or an antigen binding fragment thereof comprising at least one of the following combinations:
(1) light chain BD22088 (SEQ ID NO:229) and heavy chain BD20337 (SEQ ID NO: 148);
(2) light chain BD22090 (SEQ ID NO:234) and heavy chain BD20337 (SEQ ID NO:148);
(3) light chain BD22095 (SEQ ID NO:244) and heavy chain BD20337 (SEQ ID NO:148);
(4) light chain BD22091 (SEQ ID NO:242) and heavy chain BD20337 (SEQ ID NO:148);
(5) light chain BD22108 (SEQ ID NO:230) and heavy chain BD20337 (SEQ ID NO: 148);
(6) light chain BD22092 (SEQ ID NO:235) and heavy chain BD20338 (SEQ ID NO:149);
(7) light chain BD22094 (SEQ ID NO:231) and heavy chain BD20337 (SEQ ID NO:148);
(8) light chain BD22096 (SEQ ID NO:241) and heavy chain BD20337 (SEQ ID NO:148);
(9) light chain BD22092 (SEQ ID NO:235) and heavy chain BD20337 (SEQ ID NO: 148);
(10 light chain BD22102 (SEQ ID NO:248) and heavy chain BD20337 (SEQ ID NO:148);
(11) light chain BD22104 (SEQ ID NO:239) and heavy chain BD20337 (SEQ ID NO:148);
(12) light chain BD22103 (SEQ ID NO:228) and heavy chain BD20337 (SEQ ID NO: 148); or
(13) light chain BD22105 (SEQ ID NO:237) and heavy chain BD20337 (SEQ ID NO: 148); and
wherein the at least a portion of a light chain, the at least a portion of the heavy chain, or both are derived at least in part from sequences made by the method comprising:
(1) providing an Independently Consensused Framework I (ICFI) domain, comprising an amino acid consensus sequence derived from a plurality of amino acid sequences each comprising amino acids derived from at least a portion of a Kabat framework region I (KFI) domain, wherein the plurality of amino acid sequences are translated from a germline sequence of an immunoglobulin variable region gene or obtained from a mature immunoglobulin;
(2) providing at least a portion of a complementarity determining region 1 (CDR1) derived from the variable region of a 1FS antibody;
(3) providing an Independently Consensused Framework 2 (ICF2) domain, comprising an amino acid consensus sequence derived from a plurality of amino acid sequences each comprising amino acids derived from at least a portion of a Kabat framework region 2 (KF2) domain, wherein the plurality of amino acid sequences translated from a germline sequence of an immunoglobulin variable region gene or obtained from a mature immunoglobulin;
(4) providing at least a portion of a complementarity determining region 2 (CDR2) derived from the variable region of a IFS antibody;
(5) providing an Independently Consensused Framework 3 (ICF3) domain, comprising an amino acid consensus sequence derived from a plurality of amino acid sequences each comprising amino acids derived from at least a portion of a Kabat framework region 3 (KF3) domain, wherein the plurality of amino acid sequences are translated from a germline sequence of an immunoglobulin variable region gene or obtained from a mature immunoglobulin;
(6) providing at least a portion of a complementarity determining region 3 (CDR3) derived from the variable region of a IFS antibody; and
(7) optionally providing an Independently Consensused Framework 4 (ICF4) domain, comprising an amino acid consensus sequence derived from a plurality of amino acid sequences each comprising amino acids derived from at least a portion of a Kabat framework region 4 (KF4) domain, wherein the plurality of amino acid sequences are translated from a germline sequence of an immunoglobulin variable region gene or obtained from a mature immunoglobulin;
wherein at least one rCF is derived from a genomic nucleic acid sequence,
(8) joining, in a 5′-to-3′ orientation, nucleic acids encoding the ICF1-CDR1-ICF2-CDR2-ICF3-CDR3 and optionally ICF4 domains; and
(b) administering an amount of said antibody or antigen binding fragment thereof to an individual in need thereof sufficient to ameliorate said B-cell mediated disease in said individual.
2. A method for suppressing or abrogating a B-cell mediated immune response comprising:
(a) providing an antibody or antigen binding fragment thereof comprising at least one of the following combinations:
(1) light chain BD22088 (SEQ ID NO:229) and heavy chain BD20337 (SEQ ID NO: 148);
(2) light chain BD22090 (SEQ ID NO:234) and heavy chain BD20337 (SEQ ID NO:148);
(3) light chain BD22095 (SEQ ID NO:244) and heavy chain BD20337 (SEQ ID NO:148);
(4) light chain BD22091 (SEQ ID NO:242) and heavy chain BD20337 (SEQ ID NO: 148);
(5) light chain BD22108 (SEQ ID NO:230) and heavy chain BD20337 (SEQ ID NO: 148);
(6) light chain BD22092 (SEQ ID NO:235) and heavy chain BD20338 (SEQ ID NO:149);
(7) light chain BD22094 (SEQ ID NO:231) and heavy chain BD20337 (SEQ ID NO: 148);
(8) light chain BD22096 (SEQ ID NO:241) and heavy chain BD20337 (SEQ ID NO:148);
(9) light chain BD22092 (SEQ ID NO:235) and heavy chain BD20337 (SEQ ID NO:148);
(10 light chain BD22102 (SEQ ID NO:248) and heavy chain BD20337 (SEQ ID NO:148);
(11) light chain BD22104 (SEQ ID NO:239) and heavy chain BD20337 (SEQ ID NO: 148);
(12) light chain BD22103 (SEQ ID NO:228) and heavy chain BD20337 (SEQ ID NO:148); or
(13) light chain BD22105 (SEQ ID NO:237) and heavy chain BD20337 (SEQ ID NO:148); and
wherein the at least a portion of a light chain, the at least a portion of the heavy chain, or both are derived at least in part from sequences made by the method comprising:
(1) providing an Independently Consensused Framework I (ICFI) domain, comprising an amino acid consensus sequence derived from a plurality of amino acid sequences each comprising amino acids derived from at least a portion of a Kabat framework region I (KFI) domain, wherein the plurality of amino acid sequences are translated from a germline sequence of an immunoglobulin variable region gene or obtained from a mature immunoglobulin;
(2) providing at least a portion of a complementarity determining region 1 (CDR 1) derived from the variable region of a IFS antibody;
(3) providing an Independently Consensused Framework 2 (ICF2) domain, comprising an amino acid consensus sequence derived from a plurality of amino acid sequences each comprising amino acids derived from at least a portion of a Kabat framework region 2 (KF2) domain, wherein the plurality of amino acid sequences translated from a germ line sequence of an immunoglobulin variable region gene or obtained from a mature immunoglobulin;
(4) providing at least a portion of a complementarity determining region 2 (CDR2) derived from the variable region of a IFS antibody;
(5) providing an Independently Consensused Framework 3 (ICF3) domain, comprising an amino acid consensus sequence derived from a plurality of amino acid sequences each comprising amino acids derived from at least a portion of a Kabat framework region 3 (KF3) domain, wherein the plurality of amino acid sequences are translated from a germline sequence of an immunoglobulin variable region gene or obtained from a mature immunoglobulin;
(6) providing at least a portion of a complementarity determining region 3 (CDR3) derived from the variable region of a IFS antibody; and
(7) optionally providing an Independently Consensused Framework 4 (ICF4) domain, comprising an amino acid consensus sequence derived from a plurality of amino acid sequences each comprising amino acids derived from at least a portion of a Kabat framework region 4 (KF4) domain, wherein the plurality of amino acid sequences are translated from a germ line sequence of an immunoglobulin variable region gene or obtained from a mature immunoglobulin;
wherein at least one rCF is derived from a genomic nucleic acid sequence,
(8) joining, in a 5′-to-3′ orientation, nucleic acids encoding the ICF1-CDR1-ICF2-CDR2-ICF3-CDR3 and optionally ICF4 domains; and
(b) administering an amount of said antibody or antigen binding fragment thereof to an individual in need thereof sufficient to suppress or abrogate said B-cell mediated immune response in said individual.
3. A method of treating B-cell lymphoma comprising:
(a) providing an antibody or antigen binding fragment thereof comprising at least one of the following combinations:
(1) light chain BD22088 (SEQ ID NO:229) and heavy chain BD20337 (SEQ ID NO: 148);
(2) light chain BD22090 (SEQ ID NO:234) and heavy chain BD20337 (SEQ ID NO:148);
(3) light chain BD22095 (SEQ ID NO:244) and heavy chain BD20337 (SEQ ID NO:148);
(4) light chain BD22091 (SEQ ID NO:242) and heavy chain BD20337 (SEQ ID NO: 148);
(5) light chain BD22108 (SEQ ID NO:230) and heavy chain BD20337 (SEQ ID NO: 148);
(6) light chain BD22092 (SEQ ID NO:235) and heavy chain BD20338 (SEQ ID NO:149);
(7) light chain BD22094 (SEQ ID NO:231) and heavy chain BD20337 (SEQ ID NO: 148);
(8) light chain BD22096 (SEQ ID NO:241) and heavy chain BD20337 (SEQ ID NO:148);
(9) light chain BD22092 (SEQ ID NO:235) and heavy chain BD20337 (SEQ ID NO:148);
(10 light chain BD22102 (SEQ ID NO:248) and heavy chain BD20337 (SEQ ID NO:148);
(11) light chain BD22104 (SEQ ID NO:239) and heavy chain BD20337 (SEQ ID NO: 148);
(12) light chain BD22103 (SEQ ID NO:228) and heavy chain BD20337 (SEQ ID NO:148); or
(13) light chain BD22105 (SEQ ID NO:237) and heavy chain BD20337 (SEQ ID NO:148); and
wherein the at least a portion of a light chain, the at least a portion of the heavy chain, or both are derived at least in part from sequences made by the method comprising:
(1) providing an Independently Consensused Framework I (ICFI) domain, comprising an amino acid consensus sequence derived from a plurality of amino acid sequences each comprising amino acids derived from at least a portion of a Kabat framework region I (KFI) domain, wherein the plurality of amino acid sequences are translated from a germline sequence of an immunoglobulin variable region gene or obtained from a mature immunoglobulin;
(2) providing at least a portion of a complementarity determining region 1 (CDR 1) derived from the variable region of a IFS antibody;
(3) providing an Independently Consensused Framework 2 (ICF2) domain, comprising an amino acid consensus sequence derived from a plurality of amino acid sequences each comprising amino acids derived from at least a portion of a Kabat framework region 2 (KF2) domain, wherein the plurality of amino acid sequences translated from a germ line sequence of an immunoglobulin variable region gene or obtained from a mature immunoglobulin;
(4) providing at least a portion of a complementarity determining region 2 (CDR2) derived from the variable region of a IFS antibody;
(5) providing an Independently Consensused Framework 3 (ICF3) domain, comprising an amino acid consensus sequence derived from a plurality of amino acid sequences each comprising amino acids derived from at least a portion of a Kabat framework region 3 (KF3) domain, wherein the plurality of amino acid sequences are translated from a germline sequence of an immunoglobulin variable region gene or obtained from a mature immunoglobulin;
(6) providing at least a portion of a complementarity determining region 3 (CDR3) derived from the variable region of a IFS antibody; and
(7) optionally providing an Independently Consensused Framework 4 (ICF4) domain, comprising an amino acid consensus sequence derived from a plurality of amino acid sequences each comprising amino acids derived from at least a portion of a Kabat framework region 4 (KF4) domain, wherein the plurality of amino acid sequences are translated from a germ line sequence of an immunoglobulin variable region gene or obtained from a mature immunoglobulin;
wherein at least one rCF is derived from a genomic nucleic acid sequence,
(8) joining, in a 5′-to-3′ orientation, nucleic acids encoding the ICF1-CDR1-ICF2-CDR2-ICF3-CDR3 and optionally ICF4 domains; and
(b) administering an amount of said antibody or fragment thereof to an individual in need thereof sufficient to treat said B-cell lymphoma in said patient.
4. The method of claim 3 further comprising the step of using the antibody or antigen binding fragment thereof for the manufacture of a pharmaceutical composition for said treatment the individual having the B-cell lymphoma.